Detalles de la búsqueda
1.
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Invest New Drugs
; 30(6): 2334-43, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160853
2.
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
Cell Cycle
; 10(6): 963-70, 2011 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21368575
Resultados
1 -
2
de 2
1
Próxima >
>>